Gastrointestinal adverse drug reactions and antibiotic-associated diarrhea during antibiotic therapy in outpatient practice: prevention and treatment

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):196-206

​ Zakharenko S.М., Andreeva I.V., Stetsiouk O.U.
10.36488/cmac.2019.3.196-206
antimicrobials safety adverse drug reactions diarrhea antibiotic-associated diarrhea H. pylori eradication probiotics Lactobacillus spp S. boulardii
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):196-206

Abstract

Adverse drug reactions affecting gastrointestinal tract, quite often with the development of antibioticassociated diarrhea, are the most common undesirable effects of antibiotic therapy in outpatient practice. This review provides modern approaches to the prevention and treatment of these conditions; a particular attention is paid to the possibility of improving the efficacy and safety of Helicobacter pylori eradication regimens.

Zakharenko S.М.

S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Makins R., Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2(4):421-429. DOI: 10.1517/14740338.2.4.421
  • 2. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf. 2000;22(3):237-249. DOI: 10.2165/00002018-200022030-00007
  • 3. Nassar N.N., Gregg C.R. Esophageal Infections. Curr Treat Options Gastroenterol. 1998;1(1):56-63. DOI: 10.1007/s11938-998-0009-7
  • 4. Mahon B.E., Rosenman M.B., Kleiman M.B. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139(3):380-384. DOI: 10.1067/mpd.2001.117577
  • 5. Kanner E.V., Gorelov A.V., Krutikhina S.B. Antibiotic-associated diarrhea in children: a modern view of the problem. Medicinskij sovet. 2017;1:226-230. Russian.
  • 6. Giannelli F.R. Antibiotic-associated diarrhea. JAAPA. 2017;30(10):46-47. DOI: 10.1097/01.JAA.0000524721.01579.c9
  • 7. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292-307. DOI: 10.1159/000016879
  • 8. Owens R.C. Jr., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl. 2):S144-S157. DOI: 10.1086/428055
  • 9. Salvo F., De Sarro A., Caputi A.P., Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf. 2009;8(1):111-118. DOI: 10.1517/14740330802527984
  • 10. Högenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27(4):702-710. DOI: 10.1086/514958
  • 11. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573-581. DOI: 10.1093/clind/15.4.573
  • 12. Osadchuk M.A., Svistunov A.A. Antibiotic-associated diarrhea in clinical practice.Voprosy sovremennoj pediatrii. 2014;13(1):102-108. Russian.
  • 13. Mitchell D.K., Van R., Mason E.H., Norris D.M., Pickering L.K. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Pediatr Infect Dis J. 1996;15(6):514-519. DOI: 10.1097/00006454-199606000-00008
  • 14. Vanderhoof J.A., Whitney D.B., Antonson D.L., Hanner T.L., Lupo J.V., Young R.J. Lactobacillus GG in the prevention of antibioticassociated diarrhea in children. J Pediatr. 1999;135(5):564-568. DOI: 10.1016/s0022-3476(99)70053-3
  • 15. Arvola T., Laiho K., Torkkeli S., Mykkänen H., Salminen S., Maunula L., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104(5):e64. DOI: 10.1542/peds.104.5.e64
  • 16. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22-26. DOI: 10.1097/00005176-200307000-00004
  • 17. La Rosa M., Bottaro G., Gulino N., Gambuzza F., Di Forti F., Inì G., et al. [Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study]. Minerva Pediatr. 2003;55(5):447-452. PMID: 14608267
  • 18. Seki H., Shiohara M., Matsumura T., Miyagawa N., Tanaka M., Komiyama A., et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003;45(1):86-90. DOI: 10.1046/j.1442-200x.2003.01671.x
  • 19. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590. DOI: 10.1111/j.1365-2036.2005.02356.x
  • 20. Damrongmanee A., Ukarapol N. Incidence of antibioticassociated diarrhea in a pediatric ambulatory care setting. J Med Assoc Thai. 2007;90(3):513-517. PMID: 17427529
  • 21. Ruszczyński M., Radzikowski A., Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-561. DOI: 10.1111/j.1365-2036.2008.03714.x
  • 22. Bargozzi E., Gaiazzi M., Meneghin F., Ramponi G., Zuccotti G., Cardile S., et al. Antibiotic associated diarrhea in children: What happens in real life? Digestive and Liver Disease. 2013;45:e263-e311. DOI: 10.1016/j.dld.2013.08.150
  • 23. Wiström J., Norrby S.R., Myhre E.B., Eriksson S., Granström G., Lagergren L., et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001;47(1):43-50. DOI: 10.1093/jac/47.1.43
  • 24. Peeters T.L., Matthys G., Depootere I., Cachet T., Hoogmartens J., Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol. 1989;257:470-474. DOI: 10.1152/ajpgi.1989.257.3.G470
  • 25. Caron F., Bouaniche M., Delatour F., Ducrotte P., Torlotin J.C., Denis P., et al. B. Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob Agents Chemother. 1996;40:1796-800. PMID: 8843283
  • 26. Shevyakov M.A. Antibiotic-associated diarrhea and intestinal candidiasis: treatment and prevention options. Antibiotiki i himioterapija. 2004;49(10):26-29. Russian.
  • 27. Jernberg C., Lofmark S., Edlund C., Jansson J.K. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1:56-66. DOI: 10.1038/ismej.2007.3
  • 28. Sjölund M., Tano E., Blaser M.J., Andersson D.I., Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerg Infect Dis. 2005;11:1389-1393. DOI: 10.3201/eid1109.050124
  • 29. Jakobsson H., Wreiber K., Fall K., Fjelstad B., Nyrén O., Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39:757-763. DOI: 10.1080/00365540701299608
  • 30. Löfmark S., Jernberg C., Jansson J.K., Edlund C. Clindamycininduced enrichment and longterm persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006,58:1160-1167. DOI: 10.1093/jac/dkl420
  • 31. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing. PLoS Biol. 2008;6(11):e280. DOI: 10.1371/journal.pbio.0060280
  • 32. Zaura E., Brandt B.W., Teixeira de Mattos M.J., Buijs M.J., Caspers M.P., Rashid M.U., et al. Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces. MBio. 2015;6(6):e01693-15. DOI: 10.1128/mBio.01693-15
  • 33. Palleja A., Mikkelsen K.H., Forslund S.K., Kashani A., Allin K.H., Nielsen T., et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-1265. DOI: 10.1038/s41564-018-0257-9
  • 34. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67:302-307. PMID: 9864230
  • 35. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324(7350):1361. DOI: 10.1136/bmj.324.7350.1361
  • 36. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16(8):1461-1467. DOI: 10.1046/j.1365-2036.2002.01318.x
  • 37. Johnston B.C., Supina A.L., Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ. 2006;175(4):377-383. DOI: 10.1503/cmaj.051603
  • 38. Szajewska H., Ruszczyński M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-372. DOI: 10.1016/j.jpeds.2006.04.053
  • 39. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. DOI: 10.1002/14651858.CD004827.pub3
  • 40. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and metaanalysis. JAMA. 2012;307(18):1959-1969. DOI: 10.1001/jama.2012.3507
  • 41. Goldenberg J.Z., Ma S.S., Saxton J.D., Lo C.K., Beardsley J., Mertz D., et al. Probiotics for the prevention of Clostridium difficileassociated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095. DOI: 10.1002/14651858.CD006095.pub3
  • 42. McFarland L.V. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. Benef Microbes. 2015;6(2):189-194. DOI: 10.3920/BM2014.0034
  • 43. Goldenberg J.Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;12:CD004827. DOI: 10.1002/14651858.CD004827.pub4
  • 44. Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibioticassociated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157. DOI: 10.1111/apt.13404
  • 45. Jafarnejad S., Shab-Bidar S., Speakman J.R., Parastui K., Daneshi-Maskooni M., Djafarian K. Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) but Not the Elderly (>65 Years): A Meta-Analysis. Nutr Clin Pract. 2016;31(4):502-513. DOI: 10.1177/0884533616639399
  • 46. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., et al. Probiotics for the prevention of Clostridium difficileassociated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12: CD006095. DOI: 10.1002/14651858.CD006095.pub4
  • 47. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With MetaRegression Analysis. Gastroenterology. 2017;152(8):1889-1900. DOI: 10.1053/j.gastro.2017.02.003
  • 48. Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients – A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4). pii: E21. DOI: 10.3390/antibiotics6040021
  • 49. Guo Q., Goldenberg J.Z., Humphrey C., El Dib R., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827. DOI: 10.1002/14651858.CD004827.pub5
  • 50. WGO Practice Guideline. Probiotics and Prebiotics. World Gastroenterology Organization. 2012. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. Accessed 20.10.2019.
  • 51. Szajewska H., Canani R.B., Guarino A., Hojsak I., Indrio F., Kolacek S., et al; ESPGHAN Working Group for Probiotics and Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. DOI: 10.1097/MPG.0000000000001081
  • 52. Guarner F., Sanders M.E., Eliakim R., Fedorak R., Gangl A., Garish J., et al.; World Gastroenterology Organization Global Guidelines. Probiotics and prebiotics. February 2017. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english. Accessed 20.10.2019.
  • 53. Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI: 10.1136/gutjnl-2016-312288
  • 54. Wermeille J., Cunningham M., Dederding J.P., Girard L., Baumann R., Zelger G., et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219. PMID: 11981460
  • 55. Sanches B., Coelho L., Moretzsohn L., Vieira G. Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13(6):572-576. DOI: 10.1111/j.1523-5378.2008.00649.x
  • 56. Gong Y., Li Y., Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a metaanalysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530-6543. PMID: 26131283
  • 57. Bulgakov S.A. Side effects of antihelicobacter therapy. Al'manah klinicheskoj mediciny. 2006;14:20-23. Russian.
  • 58. Marteau P., Rambaud J.C. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev. 1993;12:207-220. DOI: 10.1111/j.1574-6976.1993.tb00019.x
  • 59. Armuzzi A., Cremonini F., Ojetti V., Bartolozzi F., Canducci F., Candelli M., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion. 2001;63(1):1-7. DOI: 10.1159/000051865
  • 60. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-168. DOI: 10.1111/j.1365-2036.2006.03179.x
  • 61. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(5):97-107. DOI: 10.1111/j.1523-5378.2009.00716.x
  • 62. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacteriumcontaining probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. DOI: 10.1097/MCG.0b013e318266f6cf
  • 63. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453. DOI: 10.4321/s1130-01082013000800002
  • 64. Li S., Huang X.L., Sui J.Z., Chen S.Y., Xie Y.T., Deng Y., et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173(2):153-161. DOI: 10.1007/s00431-013-2220-3
  • 65. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-4347. DOI: 10.3748/wjg.v21.i14.4345
  • 66. Lü M., Yu S., Deng J., Yan Q., Yang C., Xia G., et al. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0163743. DOI: 10.1371/journal.pone.0163743
  • 67. Si X.B., Lan Y., Qiao L. A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori. Zhonghua Nei Ke Za Zhi. 2017;56(10):752-759. DOI: 10.3760/cma.j.issn.0578-1426.2017.10.009
  • 68. Fang H.R., Zhang G.Q., Cheng J.Y., Li Z.Y. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7-16. DOI: 10.1007/s00431-018-3282-z
  • 69. Lv Z., Wang B., Zhou X., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A metaanalysis. Exp Ther Med. 2015;9(3):707-716. DOI: 10.3892/etm.2015.2174
  • 70. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180
  • 71. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al.; European Helicobacter Study Group Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report. Gut. 2012;61(5):646-664. DOI: 10.1136/gutjnl-2012-302084
Views
0 Abstract
0 PDF
0 Crossref citations
Shared